Introduction
Health systems struggle to deliver guideline-recommended multidisciplinary care to patients with chronic digestive disease. Digital collaborative care models (DCCMs) that integrate technology with experienced providers continue to advance within gastroenterology practice, and have potential to mitigate these barriers. To date, the majority are tailored for chronic bowel conditions like inflammatory bowel disease. We previously reported on positive outcomes for patients with irritable bowel syndrome in the United States who enrolled in the Ayble Health DCCM. We aimed to evaluate the program’s efficacy to improve clinical outcomes in patients with chronic upper gastrointestinal (UGI) conditions.
Aims & Methods
Analysis of prospective, longitudinal metrics for adult patients with UGI conditions enrolled in the Ayble Health program for a minimum of 4 weeks between Jan 1, 2024 and Feb 1, 2026. Participants engaged in at least 1 care pathway: (1) a multidisciplinary care team (gastroenterologist, nurse practitioner, certified health coach, dietitian), (2) nutrition program with a 4-phase personalized elimination diet (identification, elimination, reintroduction, maintenance), (3) brain–gut behavioral therapy (BGBT; cognitive-behavioral therapy, gut-directed hypnotherapy, and/or acceptance and commitment therapy). Audio and text materials are based on the established literature applying these concepts to UGI. The DCCM is supported by AI algorithms to identify and communicate key outcome trends to personalize care plans. Baseline and follow-up total scores of the Patient Assessment of Upper Gastrointestinal Disorders-Symptom Severity Index (PAGI-SYM) short-form developed for mobile applications were collected. Scores range from 0 (none) to 5 (very severe). Published guidelines suggest a ≥ 30% reduction is clinically significant.
Results
126 patients enrolled. The 81% (n=102) who engaged for at least 4 weeks were analyzed: average age 45.76 years, 82% female, 89% white. 75% had 1 upper GI condition and 25% had 2 or more. 92% had Gastro-Esophageal Reflux Disease, 15% Functional Dyspepsia, 12% Eosinophilic Esophagitis, 10% Gastritis, 2% Peptic Ulcer. Average baseline PAGI-SYM score was 1.82 (SD = 1.04, range: 0 - 4.83). Nearly all (93%) patients used the Care Team, 98% used the Nutrition Program, and 70% BGBT; 68% used all three programs. Patients engaged in the DCCM 130 (SD = 76.99) days, logged 22.7 (SD = 22.09) symptom surveys, and had 5.1 (SD = 3.52) care team visits, on average. The average PAGI-SYM score decreased from 1.82 at intake to 0.96 at follow-up (p<.001, partial eta squared = 0.24), with 67% of patients having clinically significant improvement (at least 30% PAGI-SYM reduction). PAGI-SYM score decreased to 1.04 by week 4 (1.63 decrease, p<.001, Cohen’s d = -0.92) and stabilized at 0.77 by week 17 and beyond (p < .001, d = 1.09). Week 4 and week 17 scores did not significantly differ (p=.20), demonstrating durability of the treatment effects.
Conclusion
Similar to our findings in IBS, patients achieved significant reductions in symptoms while utilizing a DCCM tailored for UGI conditions. These improvements were durable for up to 17 weeks. DCCMs may be highly adaptive to successfully deliver evidence-based multidisciplinary care to patients with chronic UGI symptoms, with clinically significant and sustained symptom relief. Randomized clinical trials are recommended to assess cost and treatment efficacy compared to standard of care approaches.
References
Lupe, S.E., Olson, J.M., Kamp, K., Heitkemper, M., Pathipati, M.P., Simons, M.L., Brown, J., Jactel, S.N., Regueiro, M., Lembo, A. and Taft, T.H. (2025), First Real-World Evidence of an AI-Enhanced Digital Collaborative Care Model to Improve IBS Symptoms. Neurogastroenterology & Motility, 37: e70144. https://doi.org/10.1111/nmo.70144
Disclosure
Tiffany Taft, Stephen Lupe, Kendra Kamp, Margaret Heitkemper are Scientific Advisors for Ayble Health. Joseph Olsen and Samuel Jactel are employed by Ayble Health.